← ANALYST RATINGS · TIPRANKS
PTC Therapeutics (PTCT): analyst forecast and price target
Analyst consensus
Moderate Buy9 Buy2 Hold1 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $95.70, the highest $137, the lowest $62.00. The average is +61.5% from the last price of $59.24.
Analyst ratings 21
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $66.00 → $60.00−9.1% | Hold | +1.3% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $64.00 → $58.00−9.4% | Hold | −2.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $65.00 → $59.00−9.2% | Hold | −0.4% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $64.00 → $58.00−9.4% | Hold | −2.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $66.00 → $60.00−9.1% | Hold | +1.3% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $64.00 → $58.00−9.4% | Hold | −2.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| Unknown Analyst | Truist Financial | $62.00 | Hold | +4.7% | Initiated | 16.10.26on TipRanks 09:20 | −1.8% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $80.00 → $90.00+12.5% | Buy | +51.9% | Assigned | 14.10.26on TipRanks 19:50 | +1.9%next day −1.8% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Buy | — | Reiterated | 14.10.26on TipRanks 08:25 | +0.7%next day +1.9% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Buy | — | Reiterated | 09.10.26on TipRanks 06:11 | +2.8%next day −2.7% · 5 days −6.5% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $85.00 → $75.00−11.8% | Hold | +26.6% | Reiterated | 07.10.26on TipRanks 07:11 | −0.5%next day −0.6% · 5 days −4.6% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $122 | Buy | +105.9% | Reiterated | 07.10.26on TipRanks 03:55 | −0.5%next day −0.6% · 5 days −4.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $74.00 → $66.00−10.8% | Hold | +11.4% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $72.00 → $64.00−11.1% | Hold | +8.0% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $73.00 → $65.00−11.0% | Hold | +9.7% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $72.00 → $64.00−11.1% | Hold | +8.0% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $72.00 → $66.00−8.3% | Hold | +11.4% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $73.00 → $64.00−12.3% | Hold | +8.0% | Reiterated | 22.09.26on TipRanks 02:05 | — | |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $130 → $137+5.4% | Buy | +131.3% | Assigned | 21.09.26on TipRanks Sep 22 08:10 | −1.7%next day +1.1% · 5 days +2.1% | ↗ |
| Name not given | — | $70.00 → $98.00+40.0% | Buy | +65.4% | Initiated | 14.09.26on TipRanks 12:15 | +1.1%next day −0.8% · 5 days −3.7% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $109 | Buy | +84.0% | Reiterated | 02.09.26on TipRanks 11:00 | +1.3%next day −1.6% · 5 days −5.2% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | $90.00 | Buy | +51.9% | Reiterated | 30.08.26on TipRanks Aug 31 02:40 | −0.5%next day +2.2% · 5 days −0.9% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $120 → $122+1.7% | Buy | +105.9% | Reiterated | 13.08.26on TipRanks Aug 14 04:35 | −1.6%next day −0.2% · 5 days −0.1% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $96.00 | Buy | +62.1% | Reiterated | 13.08.26on TipRanks 08:50 | −1.6%next day −0.2% · 5 days −0.1% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $93.00 → $104+11.8% | Buy | +75.6% | Reiterated | 31.07.26on TipRanks 07:06 | −10.7%next day −1.3% · 5 days +4.3% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $85.00 | Hold | +43.5% | Reiterated | 30.07.26on TipRanks Jul 31 10:32 | −0.3%next day −10.7% · 5 days −9.8% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $70.00 | Sell | +18.2% | Reiterated | 30.07.26on TipRanks Jul 31 08:19 | −0.3%next day −10.7% · 5 days −9.8% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $89.00 → $91.00+2.2% | Buy | +53.6% | Reiterated | 13.07.26on TipRanks 07:43 | −3.4%next day −4.4% · 5 days −3.1% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $75.00 → $108+44.0% | Buy | +82.3% | Initiated | 10.06.26on TipRanks Jun 9 05:55 | +4.3%next day +1.1% · 5 days −2.4% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $76.00 → $85.00+11.8% | Buy | +43.5% | Upgrade | 27.05.26on TipRanks 09:00 | +4.5%next day 0.0% · 5 days −3.3% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $86.00 → $95.00+10.5% | Buy | +60.4% | Reiterated | 08.05.26on TipRanks 07:30 | +13.4%next day +4.1% · 5 days −3.2% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Buy | — | Reiterated | 27.02.26on TipRanks 09:05 | +0.6%next day −2.7% · 5 days −5.9% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 20.02.26on TipRanks 04:55 | +0.4%next day +0.8% · 5 days −3.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering PTC Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $100 at a price of $64.78 (+54.7%); now: $95.70 at $59.24 (+61.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 9 | 11 | 8 |
| Buy | 9 | 10 | 14 | 10 | 10 | 5 |
| Hold | 5 | 4 | 5 | 3 | 3 | 2 |
| Sell | 0 | 0 | 1 | 1 | 1 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.21 (from $-1.06 to $0.96). Last quarter: $0.92.
Sales
Next quarter’s sales estimate — $304M (from $274M to $322M). Last quarter: $361M.
Best top-analyst consensus in the sector · Healthcare
About PTC Therapeutics
- CEO: Matthew Klein
- Employees: 991
- 500 Warren Corporate Center Drive, Warren, NJ, 07059, US
- www.ptcbio.com
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Data from the stock’s TipRanks forecast page, read 46 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗